Cargando…

Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?

Androgen deprivation therapy (ADT) is the longstanding treatment for advanced prostate cancer (PC) because androgen receptor (AR) is the key therapeutic vulnerability for this disease. Bipolar androgen therapy (BAT) — the rapid cycling of supraphysiologic androgen (SPA) and low serum testosterone le...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peinetti, Nahuel, Bilusic, Marijo, Burnstein, Kerry L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711867/ https://www.ncbi.nlm.nih.gov/pubmed/36453547 http://dx.doi.org/10.1172/JCI165357

Ejemplares similares

Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
por: Denmeade, Samuel R, et al.
Publicado: (2023)

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
por: Sena, Laura A., et al.
Publicado: (2022)

The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor
por: Copello, Valeria A., et al.
Publicado: (2022)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

Novel lipid mediators contributing to androgen receptor therapy resistance in prostate cancer
por: Chinni, Sreenivasa R.
Publicado: (2021)

Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer
por: Martinez, Maria J., et al.
Publicado: (2023)

Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
por: Kohli, Manish, et al.
Publicado: (2012)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
por: Chuu, Chih-Pin, et al.
Publicado: (2011)

Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy
por: Zhang, Keke, et al.
Publicado: (2018)

A Novel Nuclear Role for the Vav3 Nucleotide Exchange Factor in Androgen Receptor Coactivation in Prostate Cancer
por: Rao, Shuyun, et al.
Publicado: (2011)

Inefficient N2-Like Neutrophils Are Promoted by Androgens During Infection
por: Scalerandi, María V., et al.
Publicado: (2018)

Towards understanding androgen receptor-independent prostate cancer: an evolving paradigm
por: Zhou, Jianfu, et al.
Publicado: (2020)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer
por: Wen, Simeng, et al.
Publicado: (2020)

A phosphorylation switch controls androgen biosynthesis in prostate cancer
por: Qiu, Yun
Publicado: (2023)

Biological and Clinical Significance of Androgens and Androgen Receptor in Prostate Cancer
por: Koochekpour, Shahriar
Publicado: (2014)

Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy
por: Chen, Jia-Feng, et al.
Publicado: (2019)

Statins and adrenal androgen levels in prostate cancer: A new twist
por: Mostaghel, Elahe A
Publicado: (2021)

The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
por: Eisermann, Kurtis, et al.
Publicado: (2017)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
por: Culig, Zoran
Publicado: (2021)

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)

Selective androgen receptor modulators: the future of androgen therapy?
por: Christiansen, Andrew R., et al.
Publicado: (2020)

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Protein translation controlled by the androgen receptor in prostate cancer: a novel therapeutic option?
por: Mirzakhani, Kimia, et al.
Publicado: (2020)

Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens
por: Dart, D. A., et al.
Publicado: (2011)

The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
por: Aragon-Ching, Jeanny B.
Publicado: (2014)

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
por: Zhang, Haozhe, et al.
Publicado: (2022)

An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells
por: Azeem, Waqas, et al.
Publicado: (2017)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Bipolar androgen therapy (BAT): A patient's guide
por: Denmeade, Samuel, et al.
Publicado: (2022)

Metabolic Roles of Androgen Receptor and Tip60 in Androgen-Dependent Prostate Cancer
por: Tan, Kah Ni, et al.
Publicado: (2020)

Plasma Androgen Receptor in Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
por: Fiorica, Francesco, et al.
Publicado: (2022)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer
por: Samaranayake, Govindi J., et al.
Publicado: (2017)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

SHH-N non-canonically sustains androgen receptor activity in androgen-independent prostate cancer cells
por: Trnski, Diana, et al.
Publicado: (2021)

Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_5tgj3hhm6061gcvdd6r8orkbe1